These investigations about immune infiltration and tumor environment indicated that the Wild group patients might have a higher immunotherapy response rate due to the TME status and the KEAP1/NFE2L2/CUL3 alterations that contribute to the tumor immune escape and “cold” tumor's formation.7 The gene discussed is NFE2L2; the disease is neoplasm.